April 12th 2021|J.Med.Chem 2021|Bispecific Estrogen Receptor α Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening Bispecific degraders (PROTACs) of ERα are expected to be advantageous over current inhibitors of ERα signaling (aromatase inhibitors/SERMs/SERDs) used to treat ER+ breast cancer. Information from DNA-encoded chemical library (DECL) screening provides a method to identify novel PROTAC […]
Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks WARMINSTER, PA, WALTHAM, MA, MUNICH, GERMANY, April 1, 2021 — Arbutus Biopharma Corporation (NASDAQ: ABUS), X-Chem, Inc. (X-Chem) and Proteros biostructures GmbH (Proteros) announced today that they have entered […]
Collaboration Includes Licensing of Preclinical Small Molecule Program WALTHAM, Mass.; Feb. 2, 2021 (Business Wire) – X-Chem, Inc., a global leader in DNA-Encoded Library (DEL) technology to identify novel drug leads, announced today that it has entered into a research collaboration and license agreement with Genentech, a member of the Roche Group. The goal of […]
Acquisition allows X-Chem to offer a more comprehensive, integrated, screen-to-lead drug discovery process to pharma and biotech clients IntelliSyn’s Founder and CEO Jeffrey Albert to join X-Chem management team Waltham, Mass., US: Jan. 26, 2021 (Business Wire) – X-Chem, Inc. (X-Chem), the industry-leading provider of DNA-Encoded Library (DEL)-based discovery services, has acquired IntelliSyn, a Montreal-based […]
Servier and X-Chem Announce Drug Discovery Collaboration in Neurological Diseases Paris and Waltham, Mass.; Jan. 6, 2021 (Business Wire) – Servier, a global pharmaceutical Group and X-Chem, Inc., a privately held drug discovery company announced today a partnership to identify and develop novel small molecules for the treatment of neurological disorders. Under the terms of […]
Waltham, Mass – January 4, 2020 – X-Chem Inc. (X-Chem), the global leader in DNA-Encoded Library (DEL) technology to identify novel drug leads, announced today that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has licensed a second drug discovery program from X-Chem.
Munich, Germany and Waltham, Mass –October 1, 2020 – Proteros Biostructures GmbH (Proteros) and X-Chem, Inc. (X-Chem) announced today the launch of an alliance with the goal of offering Hit-Identification and Target-to-Lead drug discovery services based on their complementary technology platforms. The alliance combines Proteros’ strengths in protein sciences, structural biology (crystallography and CryoEM), and […]
Waltham, Mass – July 22, 2020 – X-Chem, Inc. (X-Chem), the global leader in DNA-encoded small molecule library screening and drug discovery, announced today that it has met a key development milestone in its collaboration with Orexia Limited (Orexia), a company focused on developing orexin positive modulators using unique structure based drug design capabilities.
WALTHAM, Mass. – June 11, 2020 – X-Chem, Inc., the leader in DNA-encoded small molecule library screening, and ZebiAI Therapeutics, a drug discovery company unlocking new disease targets, today announced the publication of a large prospective study to evaluate the power of machine learning (ML) to accelerate and improve the drug discovery process. The study, […]
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, announces the acquisition of X-Chem, Inc. (X-Chem), the industry-leading provider of DNA-Encoded Library (DEL)-based discovery services, from an affiliate of The Carlyle Group and Hellman & Friedman LLC.